Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age25-38
SponsorUniversity Hospital, Brest
About this trial
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.
Eligibility criteria
Qualifiers
all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov